Table 4. Clinical and pathological features and PPARγ expression in follicular carcinomas.
|
PPARγ immunohistochemistry |
||||
|---|---|---|---|---|
| FTC | All (n=34) | Negative (n=16) | Positive (n=18) | P-value |
| Age at diagnosis (years±s.d.) | 55.6±16.8 | 59.4±15.7 | 52.2±17.5 | NS |
| F/M ratio | 2.4/1 | 4.3/1 | 1.6/1 | NS |
| Tumour size (cm±s.d.) | 4.1±1.9 | 3.8±1.6 | 4.4±2.2 | NS |
| Invasiveness | NS | |||
| Minimally invasive | 26 | 10 (38%) | 16 (62%) | |
| Widely invasive | 8 | 6 (75%) | 2 (25%) | |
| Poorly differentiated areas | 7 | 5 (71%) | 2 (29%) | NS |
| Local invasion | 4 | 3 (75%) | 1 (25%) | NS |
| Vascular invasion | 24 | 13 (54%) | 11 (46%) | NS |
| Distant metastasis | 7 | 6 (86%) | 1 (14%) | 0.03 |
| Clinical statusa | NS | |||
| Persistent | 5 | 4 (80%) | 1 (20%) | |
| Remission | 28 | 12 (43%) | 16 (57%) | |
| Nonthyroid neoplasias | 3 | 1 (33%) | 2 (67%) | NS |
PPAR=peroxisome proliferator-activated receptor; s.d.=standard deviation; NS=not significant.
a
Loss of follow-up of one patient.